Our Pricing

How to Switch From Nevolat to Wegovy Safely in the UK

Many patients ask about how to switch from Nevolat to Wegovy when considering alternative GLP-1 weight loss treatments in the UK. While Nevolat (tirzepatide) and Wegovy (semaglutide) both support clinically significant weight reduction, transitioning between these medications requires careful clinical oversight to maintain efficacy and minimise side effects. This guide provides evidence-based protocols for switching safely under UK prescriber supervision.

Understanding the Switch From Nevolat to Wegovy: Clinical Rationale

The decision to switch from Nevolat to Wegovy typically arises from supply considerations, cost differences, or individual response patterns. Nevolat contains tirzepatide, a dual GIP/GLP-1 receptor agonist, while Wegovy contains semaglutide, a selective GLP-1 receptor agonist. Both medications demonstrated substantial weight reduction in their respective clinical trial programmes—SURPASS trials for tirzepatide showed mean weight loss of 15-22.5% depending on dose, whilst STEP trials for semaglutide reported average reductions of 12.4-14.9% at 68 weeks [1].

When considering this transition, UK prescribers evaluate your current Nevolat dose, duration of treatment, weight loss trajectory, and tolerability profile. The switch protocol differs significantly from starting Wegovy as a treatment-naïve patient, as your body has already adapted to GLP-1 receptor stimulation. This prior exposure often allows for a more streamlined titration schedule compared to first-time users [2].

At Cured Pharmacy, our UK-registered clinical team assesses each switch request individually, ensuring the transition aligns with MHRA-approved prescribing guidelines and your specific clinical circumstances. All switches require completion of our clinical assessment to verify suitability and establish appropriate dosing.

Step-by-Step Protocol to Switch From Nevolat to Wegovy

The recommended protocol for switching from Nevolat to Wegovy depends on your current tirzepatide dose and treatment duration. For patients on Nevolat 2.5mg or 5mg, UK prescribers typically initiate Wegovy at the standard 0.25mg weekly dose, progressing through the established titration schedule (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg) with 4-week intervals [3].

Patients established on higher Nevolat doses (10mg, 12.5mg, or 15mg) may begin Wegovy at 0.5mg weekly, bypassing the initial 0.25mg step, though this remains at prescriber discretion based on your tolerability history. There is no requirement for a washout period—you simply commence Wegovy on your next scheduled injection day after your final Nevolat dose.

Timing Your Switch From Nevolat to Wegovy

Both medications are administered weekly, making the transition straightforward from a scheduling perspective. If your last Nevolat injection was on a Monday, your first Wegovy dose should be administered the following Monday. This maintains consistent weekly GLP-1 receptor stimulation without overlap or gaps that could affect glycaemic control or appetite regulation.

Some patients experience mild recurrence of appetite or reduced satiety during the first 2-3 weeks after switching, particularly when moving from higher Nevolat doses to initial Wegovy titration doses. This temporary effect typically resolves as you progress through the Wegovy dose escalation schedule [4].

Expected Outcomes When You Switch From Nevolat to Wegovy

Clinical data comparing direct switches between tirzepatide and semaglutide remains limited, but real-world evidence from UK prescribers suggests most patients maintain their weight loss trajectory when transitioning appropriately. In the STEP 1 trial, semaglutide 2.4mg produced mean weight reduction of 14.9% from baseline over 68 weeks in treatment-naïve patients [1].

Patients switching from Nevolat should anticipate continued weight loss, though the rate may differ slightly given the mechanistic differences between dual GIP/GLP-1 agonism and selective GLP-1 agonism. Individual response varies considerably—some patients report enhanced tolerability with semaglutide, whilst others prefer tirzepatide's efficacy profile. Your UK prescriber will monitor your progress through follow-up assessments to optimise outcomes.

At Cured Pharmacy, Wegovy is available from £20 offering significant cost advantages compared to Nevolat for many patients. This pricing includes UK prescriber assessment, genuine MHRA-licensed medication, and discreet next-day delivery across the UK.

Managing Side Effects During the Switch From Nevolat to Wegovy

The side effect profiles of Nevolat and Wegovy overlap substantially, as both medications modulate GLP-1 receptors. Common adverse effects include nausea, diarrhoea, constipation, and abdominal discomfort, typically most pronounced during dose escalation phases [5]. Patients already established on Nevolat often experience fewer gastrointestinal symptoms when starting Wegovy compared to treatment-naïve individuals, as your digestive system has adapted to GLP-1 agonist effects.

If you experienced specific intolerabilities on Nevolat—such as persistent nausea or injection site reactions—these may improve with semaglutide, though this varies individually. Conversely, some patients find tirzepatide better tolerated. UK prescribers recommend maintaining consistent injection technique, rotating sites weekly (abdomen, thigh, or upper arm), and taking Wegovy on the same day each week to minimise side effects.

When to Contact Your Prescriber After Switching From Nevolat to Wegovy

Seek immediate medical advice if you experience severe abdominal pain (which may indicate pancreatitis), persistent vomiting preventing fluid intake, visual changes, or signs of allergic reaction. These serious adverse events are rare but require prompt clinical evaluation [6].

For less urgent concerns—such as increased nausea compared to your Nevolat experience, injection site issues, or questions about dose progression—contact Cured Pharmacy's clinical team through your patient portal. Our UK-registered pharmacists and prescribers provide ongoing support throughout your treatment journey.

Cost Comparison: Switch From Nevolat to Wegovy for UK Patients

Pricing represents a significant consideration for many patients contemplating the switch from Nevolat to Wegovy. At Cured Pharmacy, Wegovy is available from £69.00 per pen, with transparent pricing displayed before you complete your clinical assessment. New patients receive £20 off their first order using code Weightlossnew, reducing initial costs further.

The Wegovy dosing schedule requires one pen per month during titration phases (0.25mg and 0.5mg doses provide 4 weeks of treatment per pen), progressing to maintenance dosing at 2.4mg weekly. This pricing structure offers competitive value compared to other UK-licensed weight loss injections, whilst maintaining the same rigorous clinical oversight and genuine MHRA-approved medication.

All pricing at Cured Pharmacy includes UK prescriber consultation, medication cost, and next-day delivery. There are no hidden fees or subscription requirements—you simply reorder when needed through your secure patient account.

Starting Your Switch From Nevolat to Wegovy With Cured Pharmacy

To initiate your switch from Nevolat to Wegovy through Cured Pharmacy, complete our online clinical assessment, which takes under 3 minutes. You'll provide details about your current Nevolat dose, treatment duration, weight loss progress, and any side effects experienced. Our UK-registered prescribers review every assessment individually—this is not an automated process.

If approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Medication is dispatched in 100% discreet packaging via next-day delivery to any UK address. Your patient portal provides ongoing access to clinical support, reorder functionality, and treatment monitoring tools.

Switching between weight loss medications requires the same clinical rigour as initiating treatment. Our assessment ensures Wegovy remains appropriate for your circumstances, evaluates contraindications, and establishes the safest transition protocol based on your Nevolat history. This patient-centred approach reflects our commitment to safe, effective weight management support across the UK.

What to Expect During Your Switch From Nevolat to Wegovy Assessment

The clinical assessment covers your medical history, current medications, weight loss goals, previous GLP-1 agonist experience, and any adverse effects encountered on Nevolat. Be prepared to provide your current weight, height, and details of any relevant medical conditions such as thyroid disorders, pancreatitis history, or diabetic retinopathy.

UK prescribers may recommend specific monitoring during your switch, such as tracking weight weekly for the first month or maintaining a symptom diary. This individualised approach ensures your transition is optimised for safety and efficacy, with adjustments made based on your response to Wegovy compared to your previous Nevolat treatment [7].

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2022). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38-48. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.